{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T02:52:16Z","timestamp":1772679136598,"version":"3.50.1"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1097\/bor.0000000000000266","type":"journal-article","created":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T12:46:42Z","timestamp":1455022002000},"page":"197-203","source":"Crossref","is-referenced-by-count":11,"title":["Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade"],"prefix":"10.1097","volume":"28","author":[{"given":"J. Michelle","family":"Kahlenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210128","doi-asserted-by":"crossref","first-page":"14756","DOI":"10.1038\/srep14756","article-title":"IL-1 is a DNA damage sensor linking genotoxic stress signaling to sterile inflammation and innate immunity.","volume":"5","author":"Idan","year":"2015","journal-title":"Sci Rep"},{"key":"R2-2-20210128","doi-asserted-by":"crossref","first-page":"8815","DOI":"10.1073\/pnas.0402800101","article-title":"Differences in signaling pathways by IL-1 and IL-18.","volume":"101","author":"Lee","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R3-2-20210128","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.biomaterials.2014.11.041","article-title":"Novel multimeric IL-1 receptor antagonist for the treatment of rheumatoid arthritis.","volume":"42","author":"Pasi","year":"2015","journal-title":"Biomaterials"},{"key":"R5-2-20210128","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40261-013-0127-4","article-title":"Bioequivalence of canakinumab liquid prefilled syringe and reconstituted lyophilized formulations following 150mg subcutaneous administration: a randomized study in healthy subjects.","volume":"33","author":"Chioato","year":"2013","journal-title":"Clin Drug Invest"},{"key":"R6-2-20210128","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.trsl.2015.06.006","article-title":"Targeting the inflammasome in rheumatic diseases.","volume":"167","author":"McCoy","year":"2015","journal-title":"Transl Res"},{"key":"R8-2-20210128","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.","volume":"21","author":"Coll","year":"2015","journal-title":"Nat Med"},{"key":"R9-2-20210128","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.cellsig.2015.02.025","article-title":"Interleukin-1 receptor associated kinase inhibitors: Potential therapeutic agents for inflammatory- and immune-related disorders.","volume":"27","author":"Bahia","year":"2015","journal-title":"Cell Signal"},{"key":"R11-2-20210128","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1073\/pnas.1424741112","article-title":"Cell stress increases ATP release in NLRP3 inflammasome-mediated autoinflammatory diseases, resulting in cytokine imbalance.","volume":"112","author":"Carta","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R12-2-20210128","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1002\/art.20633","article-title":"Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1PYPAF1NALP3 gene.","volume":"50","author":"Arostegui","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R13-2-20210128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1074-7613(04)00046-9","article-title":"NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder.","volume":"20","author":"Agostini","year":"2004","journal-title":"Immunity"},{"key":"R14-2-20210128","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMoa055137","article-title":"Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.","volume":"355","author":"Goldbach-Mansky","year":"2006","journal-title":"N Engl J Med"},{"key":"R15-2-20210128","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMoa0809568","article-title":"An autoinflammatory disease due to homozygous deletion of the IL1RN locus.","volume":"360","author":"Reddy","year":"2009","journal-title":"N Engl J Med"},{"key":"R16-2-20210128","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/art.39190","article-title":"Brief report: cryopyrin-associated periodic syndrome caused by a myeloid-restricted somatic nlrp3 mutation.","volume":"67","author":"Zhou","year":"2015","journal-title":"Arthritis Rheum"},{"key":"R17-2-20210128","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/annrheumdis-2015-207546","article-title":"Recommendations for the management of autoinflammatory diseases.","volume":"74","author":"ter Haar","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R19-2-20210128","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","article-title":"An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.","volume":"360","author":"Aksentijevich","year":"2009","journal-title":"N Engl J Med"},{"key":"R20-2-20210128","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.jaci.2012.07.043","article-title":"Periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome is linked to dysregulated monocyte IL-1beta production.","volume":"131","author":"Kolly","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"R21-2-20210128","doi-asserted-by":"crossref","first-page":"7148","DOI":"10.1073\/pnas.1103681108","article-title":"Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade.","volume":"108","author":"Stojanov","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R22-2-20210128","first-page":"593","article-title":"A case of resistant adult-onset periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome responsive to anakinra.","volume":"30","author":"Cantarini","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"R23-2-20210128","doi-asserted-by":"crossref","first-page":"e59327","DOI":"10.1371\/journal.pone.0059327","article-title":"Effect of in vitro and in vivo anakinra on cytokines production in Schnitzler syndrome.","volume":"8","author":"Launay","year":"2013","journal-title":"PLoS One"},{"key":"R24-2-20210128","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jaci.2014.07.050","article-title":"Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome.","volume":"135","author":"de Koning","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R25-2-20210128","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.autrev.2014.08.031","article-title":"Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzlers syndrome: a French multicenter study.","volume":"13","author":"Neel","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R26-2-20210128","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/annrheumdis-2012-202192","article-title":"Sustained efficacy of the monoclonal antiinterleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzlers syndrome.","volume":"72","author":"de Koning","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R27-2-20210128","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"key":"R28-2-20210128","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/adc.85.5.421","article-title":"Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders.","volume":"85","author":"Sawhney","year":"2001","journal-title":"Arch Dis Child"},{"key":"R29-2-20210128","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","article-title":"Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients.","volume":"50","author":"Miettunen","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R30-2-20210128","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.39407","article-title":"Canakinumab in systemic juvenile idiopathic arthritis: impact on the rate and clinical presentation of macrophage activation syndrome.","volume":"68","author":"Grom","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R31-2-20210128","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clim.2015.06.005","article-title":"Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis.","volume":"160","author":"Shimizu","year":"2015","journal-title":"Clin Immunol"},{"key":"R32-2-20210128","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1186\/ar3366","article-title":"Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Stills disease: a case-series study.","volume":"13","author":"Laskari","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R33-2-20210128","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/annrheumdis-2012-201409","article-title":"IL-1 trap rilonacept in refractory adult onset Stills disease.","volume":"71","author":"Petryna","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R34-2-20210128","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/jama.2015.12763","article-title":"Evaluation and treatment of pericarditis: a systematic review.","volume":"314","author":"Imazio","year":"2015","journal-title":"JAMA"},{"key":"R37-2-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","article-title":"Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behcets disease.","volume":"14","author":"Cantarini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R38-2-20210128","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcets disease: an open-label pilot study.","volume":"71","author":"Gul","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R39-2-20210128","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.exer.2015.06.018","article-title":"Expression profile of IL-1 family cytokines in aqueous humor and sera of patients with HLA-B27 associated anterior uveitis and idiopathic anterior uveitis.","volume":"138","author":"Zhao","year":"2015","journal-title":"Exp Eye Res"},{"key":"R40-2-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjd.13614","article-title":"Treatment of two patients with generalized pustular psoriasis with the interleukin-1 inhibitor gevokizumab.","volume":"173","author":"Mansouri","year":"2015","journal-title":"Br J Dermatol"},{"key":"R41-2-20210128","doi-asserted-by":"crossref","first-page":"70","DOI":"10.7326\/L15-5107","article-title":"Anakinra improves pyoderma gangrenosum in psoriatic arthritis: a case report.","volume":"163","author":"Acquitter","year":"2015","journal-title":"Ann Intern Med"},{"key":"R42-2-20210128","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial.","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R43-2-20210128","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000326112","article-title":"Efficacy of antiinterleukin-1 receptor antagonist anakinra (Kineret) in a case of refractory Sweets syndrome.","volume":"222","author":"Kluger","year":"2011","journal-title":"Dermatology"},{"key":"R44-2-20210128","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/ard.2006.068254","article-title":"Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome.","volume":"67","author":"Delluc","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R45-2-20210128","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1546-0096-12-30","article-title":"Deregulation of the IL-1beta axis in chronic recurrent multifocal osteomyelitis.","volume":"12","author":"Scianaro","year":"2014","journal-title":"Pediatr Rheumatol"},{"key":"R46-2-20210128","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.clim.2015.09.013","article-title":"Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1beta expression and release.","volume":"161","author":"Hofmann","year":"2015","journal-title":"Clin Immunol"},{"key":"R48-2-20210128","doi-asserted-by":"crossref","first-page":"545493","DOI":"10.1155\/2014\/545493","article-title":"Cytokines as biomarkers in rheumatoid arthritis.","volume":"2014","author":"Burska","year":"2014","journal-title":"Mediators Inflamm"},{"key":"R49-2-20210128","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.rdc.2004.01.005","article-title":"The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.","volume":"30","author":"Cohen","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"R50-2-20210128","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2474-12-153","article-title":"Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.","volume":"12","author":"Alten","year":"2011","journal-title":"BMC Musculoskelet Disord"},{"key":"R51-2-20210128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-med-060911-090007","article-title":"Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus.","volume":"64","author":"Kahlenberg","year":"2013","journal-title":"Ann Rev Med"},{"key":"R52-2-20210128","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1161\/CIRCIMAGING.113.001193","article-title":"Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis.","volume":"7","author":"Ikonomidis","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"key":"R53-2-20210128","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","article-title":"Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis.","volume":"117","author":"Ikonomidis","year":"2008","journal-title":"Circulation"},{"key":"R54-2-20210128","first-page":"e125","article-title":"Interleukin-1 blockade in rheumatoid arthritis and heart failure: a missed opportunity Int J C","volume":"171","author":"Abbate","year":"2014","journal-title":"ardiol"},{"key":"R55-2-20210128","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/1346-8138.12011","article-title":"Serum levels of interleukin-1alpha in patients with systemic sclerosis.","volume":"40","author":"Maekawa","year":"2013","journal-title":"J Dermatol"},{"key":"R56-2-20210128","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/jid.2010.120","article-title":"Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis.","volume":"130","author":"Aden","year":"2010","journal-title":"J Invest Dermatol"},{"key":"R57-2-20210128","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.humimm.2013.09.002","article-title":"Associations between interleukin 1 polymorphisms and susceptibility to systemic lupus erythematosus: a meta-analysis.","volume":"75","author":"Song","year":"2014","journal-title":"Human Immunol"},{"key":"R58-2-20210128","first-page":"109","article-title":"IL-1 beta-deficient mice are resistant to induction of experimental SLE.","volume":"17","author":"Voronov","year":"2006","journal-title":"Eur Cytokine Netw"},{"key":"R59-2-20210128","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/ard.2004.025858","article-title":"Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis.","volume":"64","author":"Ostendorf","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R60-2-20210128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome.","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"R61-2-20210128","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1136\/ard.2007.073759","article-title":"Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra.","volume":"66","author":"McGonagle","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R62-2-20210128","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/acr.21989","article-title":"Treatment of acute gouty arthritis in complex hospitalized patients with anakinra.","volume":"65","author":"Ghosh","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R63-2-20210128","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R64-2-20210128","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3899\/jrheum.131226","article-title":"Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.","volume":"41","author":"Sundy","year":"2014","journal-title":"J Rheumatol"},{"key":"R65-2-20210128","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/ar4159","article-title":"Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.","volume":"15","author":"Terkeltaub","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"R66-2-20210128","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/art.23119","article-title":"Successful treatment of resistant pseudogout with anakinra.","volume":"58","author":"McGonagle","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R67-2-20210128","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/ar4303","article-title":"Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases.","volume":"15","author":"Ottaviani","year":"2013","journal-title":"Arthritis Res Ther"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:34:50Z","timestamp":1620948890000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201605000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000266","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}